Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe, and North and South America. The trial consists of a
main trial and a sub-trial. The main trial investigates safety and efficacy of turoctocog
alfa (recombinant factor VIII, rFVIII (N8)) in haemophilia A subjects, while the sub-trial
investigates safety and efficacy of turoctocog alfa in prevention and treatment of bleeding
episodes during surgical procedures.